coronavirus
import
human
anim
pathogen
relev
increas
due
emerg
new
human
coronavirus
like
sarscov
togeth
torovirus
arterivirus
ronivirus
coronavirus
belong
order
nidoviral
far
antivir
hardli
avail
combat
infect
virus
order
therefor
variou
antivir
strategi
counter
nidovir
infect
evalu
lectin
bind
nlink
oligosaccharid
element
envelop
virus
consid
concept
new
class
viru
inhibitor
agent
recent
evalu
antivir
activ
toward
varieti
envelop
virus
shown
case
inhibit
viru
infect
low
concentr
howev
limit
knowledg
avail
efficaci
toward
nidovirus
articl
applic
plant
lectin
hippeastrum
hybrid
agglutinin
hha
galanthu
nivali
agglutinin
gna
cymbidium
sp
agglutinin
ca
urtica
dioica
agglutinin
uda
well
nonplant
deriv
pradimicina
prma
cyanovirinn
cvn
potenti
antivir
agent
evalu
three
antivir
test
compar
base
differ
evalu
principl
cell
viabil
mttbase
colorimetr
assay
number
infect
cell
immunoperoxidas
assay
amount
viral
protein
express
luciferasebas
assay
presenc
carbohydratebind
agent
strongli
inhibit
coronavirus
transmiss
gastroenter
viru
infecti
bronchiti
viru
felin
coronavirus
serotyp
ii
mous
hepat
viru
arterivirus
equin
arter
viru
porcin
respiratori
reproduct
syndrom
viru
toroviru
equin
bern
viru
remark
serotyp
ii
felin
coronavirus
arterivirus
inhibit
prma
contrast
virus
test
infect
member
order
nidoviral
seriou
health
consequ
de
clercq
nidoviral
consist
broad
group
virus
glycosyl
envelop
contain
linear
singlestrand
rna
genom
posit
polar
coronavirus
belong
order
togeth
torovirus
arterivirus
ronivirus
gorbalenya
et
al
past
control
prevent
nidoviru
infect
antivir
compound
consid
high
prioriti
regard
seriou
enough
justifi
costli
develop
specif
drug
relianc
vaccin
protect
possibl
nidovirus
see
front
matter
coronavirus
long
known
import
veterinari
pathogen
human
import
recent
increas
consider
emerg
new
human
coronavirus
sarscov
drosten
et
al
pyrc
et
al
press
outbreak
coronaviru
infect
caus
sever
acut
respiratori
syndrom
sar
proven
avail
safeti
efficaci
debat
therefor
seem
advis
develop
antinidovir
strategi
save
effect
new
antisar
coronaviru
strategi
swiftli
explor
de
clercq
becam
clear
applic
carbohydratebind
agent
cba
direct
glycosyl
envelop
virus
may
show
promis
antivir
activ
balzarini
inde
protein
bind
nlink
glycan
envelop
virus
consid
new
class
viru
inhibitor
antivir
potenti
explor
retrovirus
balzarini
et
al
balzarini
et
al
balzarini
et
al
hansen
et
al
robinson
et
al
witvrouw
et
al
cytomegaloviru
balzarini
et
al
balzarini
et
al
grail
norval
ebola
viru
barriento
et
al
hepat
c
viru
hell
et
al
influenza
b
viru
strain
limit
extent
coronavirus
balzarini
et
al
vijgen
et
al
ziolkowska
et
al
importantli
abil
lectin
bind
pathogen
explor
vivo
plant
cyanobacteriumderiv
lectin
recent
studi
microbicid
prevent
sexual
transmiss
hiv
balzarini
et
al
tsai
et
al
moreov
system
applic
compound
anim
result
acut
toxic
effect
balzarini
et
al
balzarini
et
al
balzarini
et
al
balzarini
et
al
justifi
explor
class
antivir
sever
lectin
evalu
studi
antinidovir
activ
plant
lectin
hha
hippeastrum
hybrid
agglutinin
gna
galanthu
nivali
agglutinin
kda
tetram
andor
mannos
tropism
ca
cymbidium
sp
agglutinin
kda
dimer
specif
mannos
sugar
prefer
conform
known
uda
urtica
dioica
agglutinin
among
smallest
plant
monomer
lectin
kda
size
nacetylglucosamin
specif
van
damm
et
al
interestingli
promis
nonplant
deriv
glycantarget
compound
mannosespecif
pradimicina
prma
extract
actinomycet
strain
actinomadura
hibisca
show
fungi
human
immunodefici
viru
hiv
bind
capac
tanabetochikura
et
al
also
cyanovirinn
cvn
lectin
deriv
procaryot
cyanobacterium
nostoc
ellipsosporum
specif
mannos
oligom
show
remark
antihiv
activ
boyd
et
al
dey
et
al
evalu
antivir
efficaci
compound
virus
sever
techniqu
may
use
inhibit
viru
product
cytopathogen
assess
bedard
et
al
pauwel
et
al
altern
report
gene
use
monitor
amount
infect
cell
viru
replic
olivo
westbi
et
al
studi
antivir
activ
plant
lectin
nonpeptid
antibiot
prma
procaryot
cvn
determin
member
order
nidoviral
immunocytochemistri
report
gene
express
colorimetr
mtt
assay
measur
number
infect
cell
viru
replic
cell
viabil
respect
compar
screen
method
antivir
activ
lectin
use
assay
abl
show
investig
nidovirus
sensit
carbohydratebind
agent
mannosespecif
plant
lectin
g
nivali
gna
hippeastrum
hybrid
hha
cymbidium
hybrid
ca
nacetylglucosamin
glcnac
specif
lectin
u
dioica
uda
deriv
purifi
plant
describ
previous
van
damm
et
al
pradimicina
prma
obtain
oki
igarashi
japan
purifi
recombin
cyanovirin
n
cvn
cyanobacteri
protein
produc
escherichia
coli
report
previous
mori
et
al
repres
differ
genera
order
nidoviral
investig
equin
arter
viru
porcin
reproduct
respiratori
syndrom
viru
respect
eav
prrsv
genu
arteriviru
equin
toroviru
bern
viru
genu
toroviru
sever
virus
within
genu
coronaviru
transmiss
gastroenter
viru
tgev
felin
coronavirus
fcov
belong
group
mous
hepat
viru
mhv
belong
group
ii
infecti
bronchiti
viru
ibv
poultri
member
group
iii
felin
coronavirus
evolv
sever
sublineag
two
serotyp
distinguish
evalu
felin
coronavirus
serotyp
ii
felin
fcwf
cell
obtain
nc
pedersen
uc
davi
davi
usa
use
antivir
experi
propag
fcov
serotyp
ii
fipv
strain
fcov
strain
obtain
j
evermann
washington
state
univers
usa
mckeirnan
et
al
de
haan
et
al
fcov
serotyp
fipv
black
pedersen
black
obtain
nc
pedersen
uc
davi
davi
usa
mous
cell
murin
fibroblast
cell
line
stabli
express
mhv
receptor
rossen
et
al
use
experi
propag
mhv
strain
american
type
cultur
collect
atcc
mhveflm
de
haan
et
al
mhveflm
virus
contain
firefli
luciferas
gene
respect
mhv
fipv
background
de
haan
et
al
growth
properti
infect
similar
parent
virus
de
haan
et
al
porcin
st
cell
obtain
pensaert
ugent
gent
belgium
use
experi
propag
tgev
strain
purdu
purdu
univers
west
lafayett
usa
simian
vero
cell
atcc
use
experi
propag
verocel
adapt
ibv
strain
beaudett
atcc
alonsocaplen
et
al
bern
viru
obtain
weiss
bern
univers
bern
switzerland
weiss
et
al
equin
arter
viru
eav
strain
bucyru
atcc
grown
equin
dermi
ederm
cell
atcc
abovement
cell
cultur
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
iuml
penicillin
gml
streptomycin
titrat
antivir
test
perform
dmem
contain
fb
iuml
penicillin
gml
streptomycin
life
technolog
ltd
paisley
unit
kingdom
primari
porcin
alveolar
macrophag
pam
use
experi
propag
prototyp
european
prrsv
isol
lelystad
viru
provid
g
wensvoort
central
veterinari
institut
lelystad
netherland
pam
obtain
describ
earlier
delputt
nauwynck
pam
cultiv
earl
modifi
eagl
medium
emem
supplement
fetal
bovin
serum
mm
lglutamin
bdh
chemic
ltd
pool
england
nonessenti
amino
acid
gibco
brl
mm
sodium
pyruv
mixtur
antibiot
humidifi
co
atmospher
c
cell
viabil
evalu
describ
previous
pauwel
et
al
minor
modif
ad
well
solut
bromid
mtt
sigma
chemic
co
st
loui
mo
usa
pb
final
concentr
mgml
h
incub
c
co
medium
contain
mtt
remov
cell
lyse
addit
l
dmso
well
follow
min
incub
room
temperatur
rock
plate
optic
densiti
od
valu
nm
determin
antivir
activ
base
viabil
cell
infect
tcid
tissu
cultur
infect
dose
virus
mention
presenc
variou
concentr
test
compound
virusdrug
mixtur
preincub
c
co
h
ad
cell
singl
wash
pb
deae
mixtur
remov
h
cell
wash
pb
ca
mg
test
compound
ad
concentr
mtt
assay
perform
day
fipv
fcov
day
virus
infect
complet
cpe
visibl
cell
cultur
without
addit
test
compound
compound
concentr
prevent
cytopath
effect
induc
viru
defin
effect
concentr
ec
cytotox
activ
determin
base
viabil
cell
incub
c
co
presenc
variou
concentr
test
compound
day
compound
concentr
decreas
viabil
cell
defin
cytotox
concentr
cc
pam
incub
h
variou
concentr
test
compound
dead
cell
visual
incub
mgml
ethidium
monoazid
bromid
ema
molecular
probe
fixat
paraformaldehyd
coster
et
al
stain
cell
count
fluoresc
microscopi
compound
concentr
decreas
viabil
pam
defin
cytotox
concentr
cc
antivir
activ
measur
base
reduct
number
focu
form
unit
ffu
cell
cultur
infect
nidovirus
presenc
variou
concentr
test
compound
cell
monolay
infect
multipl
infect
moi
virusdrug
mixtur
preincub
c
co
h
ad
cell
singl
wash
pb
deae
mixtur
remov
h
cell
wash
pb
ca
mg
test
compound
ad
concentr
h
postinfect
h
fipv
black
infect
fcwf
cell
fix
min
formaldehyd
subsequ
permeabil
ethanol
min
fipv
black
assess
cell
fix
h
postinfect
serotyp
coronaviru
antigen
express
fcwf
cell
appear
later
moment
compar
serotyp
ii
fcov
strain
immunoperoxidas
ipox
detect
mhvposit
cell
carri
use
rabbit
polyclon
antibodi
mhv
rottier
et
al
combin
hrp
swineantirabbit
antibodi
dako
glostrup
denmark
ascit
fluid
sampl
cat
succumb
felin
infecti
periton
use
immunodetect
fcov
fipv
black
fipv
combin
hrp
goatanticat
icn
biomed
inc
aurora
oh
usa
infect
immunoperoxidas
stain
prrsvinfect
pam
describ
earlier
delputt
nauwynck
viru
moi
preincub
h
c
differ
concentr
test
compound
ad
pam
h
cell
wash
medium
without
fetal
bovin
serum
fb
remov
unbound
viru
pam
fix
h
postinfect
min
treatment
methanol
c
fix
remov
plate
dri
kept
c
stain
fix
cell
wash
pb
rins
three
time
water
endogen
peroxidas
activ
block
incub
cell
pb
supplement
sodium
azid
h
min
prrsvinfect
cell
incub
h
c
mab
direct
prrsvnucleocapsid
protein
wieczorekkrohm
et
al
combin
hrp
goat
antimous
antibodi
dako
glostrup
denmark
infect
cell
count
use
light
microscop
effect
concentr
number
infect
cell
focu
form
unit
ffu
lower
ec
compar
mocktreat
cell
calcul
fcwf
cell
infect
mhveflm
respect
presenc
variou
concentr
test
compound
fcwf
cell
monolay
infect
multipl
infect
moi
virusdrug
mixtur
preincub
c
co
nidovirus
evalu
sensit
cba
convent
colorimetr
mtt
assay
tabl
evalu
cell
surviv
day
incub
virusinfect
cell
presenc
differ
compound
concentr
antivir
activ
compound
repres
effect
concentr
ec
case
mannosespecif
lectin
gna
hha
ca
show
antivir
activ
nidoviral
evalu
plant
lectin
gna
hha
show
ec
valu
higher
picomolar
lower
nanomolar
concentr
rang
ibv
fipv
black
tgev
tabl
replic
serotyp
ii
fcov
strain
bern
viru
equin
arter
viru
inhibit
mannosespecif
plant
lectin
concentr
rank
higher
nanomolar
concentr
rang
tabl
also
glcnacspecif
uda
show
pronounc
antivir
activ
although
less
effect
fipv
black
ibv
tgev
mannosespecif
lectin
prove
virtual
equal
activ
virus
tabl
mhv
infect
tcid
per
well
induc
massiv
syncytium
format
cell
cultur
complet
cell
lysi
within
timefram
examin
even
though
format
syncytia
seem
decreas
upon
addit
lectin
antivir
effect
reflect
od
valu
therefor
exact
ec
valu
could
determin
conclus
result
indic
strong
inhibitori
effect
plant
lectin
infect
process
nidovirus
next
immunoperoxidas
ipox
method
tabl
luciferasebas
method
tabl
use
evalu
antivir
activ
lectin
assay
base
number
infect
cell
express
viral
protein
respect
ipox
assay
mhveflm
fipv
black
fcov
prrsv
lelystad
viru
use
influenc
variou
concentr
plant
lectin
infect
virus
mhv
fcwf
fcov
strain
pam
prrsv
lelystad
viru
cell
cultur
assess
tabl
plant
lectin
ec
determin
ipox
rang
mhveflm
fcov
serotyp
ii
serotyp
felin
coronaviru
fipv
black
show
gener
markedli
higher
sensit
compound
ec
valu
vari
ipox
assay
show
case
slightli
lower
ec
compar
mtt
assay
prrsv
lelystad
viru
infect
pam
could
reduc
gna
hha
insuffici
obtain
ec
valu
indic
sensit
plant
lectin
ec
uda
applic
luciferasebas
assay
indic
similar
coronaviru
sensit
plant
lectin
luciferas
test
show
case
lower
ec
valu
compar
abovement
ipox
test
result
ec
tabl
notic
none
plant
lectin
show
appreci
cytotox
concentr
substanti
higher
antivir
activ
tabl
mtt
assay
tabl
ipox
assay
tabl
also
luciferasebas
assay
tabl
appli
evalu
sensit
nidovirus
inhibitori
activ
nonpeptid
lowmolecularweight
antibiot
pradimicina
prma
assess
virus
sensit
prma
except
fcov
serotyp
ii
strain
fcov
fipv
arterivirus
prrsv
equin
arter
viru
virus
signific
inhibit
prma
concentr
repres
maximum
solubl
compound
contrast
infect
mhveflm
fipv
black
serotyp
clearli
inhibit
prma
concentr
rang
tabl
felin
coronaviru
serotyp
fipv
black
fcov
serotyp
ii
deriv
fcwf
cell
indic
activityinact
prma
virusrel
rather
cell
typerel
overal
nidovirus
less
sensit
inhibitori
action
prma
compar
mannoseand
glcnacspecif
plant
lectin
gna
hha
uda
howev
evid
tabl
prma
show
lowmicromolar
activ
viru
strain
show
low
nanomolar
sensit
gna
hha
mark
inhibit
prma
could
observ
viru
strain
show
higher
nanomolar
sensit
gna
hha
mannosespecif
procaryot
cyanovirinn
cvn
also
evalu
antivir
activ
luciferasebas
assay
use
mhveflm
cvn
exquisit
activ
coronavirus
low
nanomolar
rang
tabl
nidovirus
assess
cytotox
cba
differ
cell
type
repres
cytotox
concentr
cc
tabl
mannosespecif
plant
lectin
hha
gna
ca
hardli
cytotox
cell
cc
uda
show
slight
cytotox
activ
cc
rang
differ
cell
type
test
pradimicina
poorli
cytotox
st
vero
cell
cc
cyanovirinn
show
cytotox
vitro
toward
fcwf
cell
cc
use
viru
propag
antivir
test
fcov
microscop
cell
chang
becam
alreadi
visibl
higher
concentr
cvn
also
cell
show
morpholog
chang
due
exposur
higher
cvn
concentr
although
overt
toxic
cc
could
notic
cell
mtt
assay
sinc
cvn
activ
low
concentr
therapeut
index
ti
still
high
cc
test
compound
low
pam
prma
show
detect
cytotox
base
mechan
antivir
activ
ie
envelop
glycan
bind
cba
want
examin
whether
correl
number
nglycosyl
site
ec
cba
therefor
made
predict
number
nglycosyl
site
use
netnglyc
server
see
web
refer
netnglyc
inpress
clear
relat
could
found
number
predict
glycosyl
site
ec
concentr
variou
cba
nidovirus
cover
mani
nglycosyl
site
envelop
protein
glycan
pose
interest
target
develop
new
target
antivir
therefor
investig
antivir
activ
glycantarget
compound
includ
mannos
glcnacbind
plant
lectin
pradimicina
prma
mannosebind
nonpeptid
antibiot
formerli
evalu
antifung
activ
cyanovirinn
cvn
mannosespecif
procaryot
lectin
glycosyl
protein
uniqu
virus
glycan
also
present
vertebr
host
cell
glycoprotein
sugar
content
viral
envelop
fulli
depend
host
cell
glycosyl
machineri
although
characterist
nglycosyl
host
cell
viru
glycoprotein
principl
similar
kept
mind
still
strike
differ
natur
glycan
found
viral
ie
hiv
hcv
envelop
glycoprotein
host
cellular
glycoprotein
hiv
hcv
glycoprotein
contain
high
amount
highmannos
type
glycan
glycan
type
much
less
abundantli
present
even
absent
mani
mammalian
glycoprotein
still
antivir
agent
specif
target
glycosyl
protein
side
effect
administ
system
potenti
problem
howev
observ
vivo
number
carbohydratebind
agent
cba
balzarini
et
al
balzarini
et
al
balzarini
et
al
balzarini
et
al
test
shortterm
toxic
shown
encourag
research
applic
cba
antinidovir
agent
assess
antivir
activ
cba
three
method
appli
differ
evalu
principl
cell
viabil
viru
infect
indic
color
format
mttbase
assay
classic
use
evalu
inhibit
viral
infect
antivir
assay
multipl
replic
step
occur
infect
process
initi
low
multipl
infect
establish
faster
accur
method
antivir
examin
coronavirus
two
altern
method
explor
ipox
luciferasebas
assay
repres
evalu
initi
infect
process
attach
entri
follow
protein
product
test
termin
viru
releas
infect
cell
therefor
contrast
mtt
assay
multipl
replic
cycl
occur
might
explain
differ
ec
valu
obtain
use
ipox
luciferasebas
assay
compar
mtt
assay
nevertheless
assay
indic
rather
similar
antivir
activ
cba
toward
nidovirus
respect
assay
interchang
therefor
possibl
use
luciferasebas
evalu
method
high
throughput
screen
may
facilit
research
antivir
direct
coronavirus
ipox
luciferas
assay
use
altern
screen
abil
cba
inhibit
mhv
sinc
mtt
assay
could
use
due
syncytium
format
follow
infect
mitochondria
giant
cell
reduc
mtt
similar
level
noninfect
control
cell
mtt
assay
efficaci
gna
hha
nidovirus
high
ec
result
rang
found
gna
hha
efficaci
siv
balzarini
et
al
sar
coronaviru
balzarini
et
al
virus
evalu
host
cell
antivir
assay
deriv
target
speci
viru
howev
use
simian
vero
cell
adapt
viru
strain
evalu
ibv
chickenbas
cell
system
avail
nonnatur
host
gener
simianlik
glycosyl
pattern
ibv
envelop
protein
might
explain
low
ec
found
plant
lectin
gna
hha
show
also
inhibitori
effect
ca
toward
fipv
mhv
earlier
studi
compound
formerli
demonstr
high
antivir
activ
retrovirus
ec
less
toward
cytomegaloviru
infect
ec
balzarini
et
al
cytomegaloviru
siv
infect
could
effici
inhibit
uda
balzarini
et
al
abl
show
uda
also
high
antivir
efficaci
evalu
nidoviral
except
prrsv
low
antivir
effect
cba
toward
prrsv
might
explain
fact
sialic
acid
structur
mainli
involv
attach
prrsv
pam
wherea
highmannos
glycan
report
less
import
delputt
nauwynck
pradimicina
mannosebind
nonpeptid
antibiot
show
antivir
activ
mhv
fipv
serotyp
tgev
ibv
efficaci
berneviru
infect
low
ec
valu
line
ec
prma
rang
found
earlier
hivinfect
cem
cytopathogen
system
giant
cell
format
assay
balzarini
et
al
tanab
et
al
despit
fact
prma
specif
dmannos
structur
fujikawa
et
al
abl
inhibit
fcov
serotyp
ii
strain
fipv
fcov
arterivirus
prrsv
eav
even
highest
concentr
evalu
somewhat
puzzl
prma
inact
fcov
serotyp
ii
strain
arterivirus
sinc
suggest
mannos
configur
tropism
iagrashi
oki
similar
cvn
addit
includ
cvn
studi
compar
reason
cyanovirinn
shown
inhibitori
effect
toward
siv
balzarini
et
al
boyd
et
al
highli
activ
mhv
fipv
serotyp
ii
infect
determin
luciferasebas
assay
lower
nanomolar
rang
therefor
conclud
glycan
contain
structur
present
fipv
serotyp
ii
mhv
virus
propag
cultur
system
discrep
prma
antivir
activ
toward
fcov
serotyp
ii
might
due
differ
receptor
usag
influenc
entir
infect
process
smith
heleniu
serotyp
ii
fcov
util
fapn
tresnan
et
al
primari
receptor
wherea
serotyp
coronavirus
attach
host
cell
reli
differ
molecul
current
unknown
hohdatsu
et
al
altern
sinc
serotyp
coronavirus
also
less
sensit
hha
gna
prma
may
activ
virus
well
drug
activ
concentr
reach
due
insolubl
compound
examin
whether
differ
cba
ec
valu
would
reflect
amount
predict
nglycosyl
site
present
viral
envelop
evalu
correl
number
nglycosyl
site
ec
found
assum
actual
number
glycosyl
site
influenc
also
glycan
type
present
ie
highmannosetyp
versu
complexhybridtyp
protein
abund
viral
envelop
may
even
import
plant
lectin
mainli
involv
recognit
process
either
within
outsid
plant
bind
carbohydr
van
damm
et
al
natur
situat
may
also
play
import
role
defens
mechan
plant
vierheilig
et
al
similar
molecul
particip
innat
immun
system
vertebr
specif
bind
glycosyl
protein
pathogen
hart
et
al
cba
bind
mannos
gna
hha
ca
cvn
prma
glcnac
uda
expect
bind
select
glycosyl
site
specif
manner
mannos
glcnac
molecul
present
throughout
glycosyl
protein
cba
may
concomitantli
bind
sever
glycan
viru
envelop
howev
mention
cba
usual
show
poor
recognit
monosaccharid
affin
select
much
higher
specif
carbohydr
oligom
configur
properti
may
also
explain
differ
potenc
cba
differ
virus
even
within
viru
famili
lectin
use
test
inhibit
infect
seem
virucid
properti
adsorpt
host
cell
viru
presenc
compound
still
lead
product
infect
upon
remov
lectin
unpublish
result
hiv
envelop
sugar
suggest
involv
retrovir
mechan
escap
host
immun
blay
et
al
reitter
et
al
rudd
et
al
wei
et
al
glycosyl
coronaviru
envelop
protein
suggest
serv
similar
purpos
ansari
et
al
chakraborti
et
al
one
specul
target
protect
shield
carbohydratebind
agent
virus
forc
gener
mutant
delet
alter
glycosyl
site
alreadi
demonstr
occur
hiv
presenc
sever
type
cba
ie
plant
lectin
prma
cvn
balzarini
et
al
balzarini
et
al
balzarini
et
al
balzarini
et
al
consequ
immunogen
epitop
expos
immun
system
balzarini
result
trigger
product
neutral
antibodi
cellular
immun
respons
uncov
immunogen
epitop
therapi
chronic
viru
infect
benefit
strategi
whether
also
appli
nidovir
infect
uncertain
although
virus
remain
anim
bodi
prolong
time
period
glaser
et
al
herrewegh
et
al
naqi
et
al
summari
studi
shown
cba
antivir
activ
toward
nidovirus
member
nidoviral
order
usual
induc
diseas
acut
prolong
charact
system
applic
therapeut
agent
seem
appropri
low
vivo
toxic
high
vitro
efficaci
encourag
continu
explor
compound
antivir
